期刊文献+

优化药物研发的临床试验模拟发展、应用及思考 被引量:1

Development,applications,and considerations of clinical trialsimulation that optimizes drug discovery
原文传递
导出
摘要 现代制药行业正在从传统方法向人工智能等先进技术过渡,不断将建模和模拟纳入药物发现、开发、设计和优化。在药物临床试验背景下,临床试验模拟(clinical trial simulation, CTS)技术综合相关信息,在药物研发的各个阶段发挥作用,已成为支持决策制定和减少临床试验失败的有用工具,得到医药企业和监管部门的广泛认可。本文参考国内外相关最新文献和指导原则,梳理临床试验模拟的发展历程、核心方法、应用范围等,旨在帮助研究者更好地认识和理解该技术在药物研究,尤其是新药研发领域的应用及价值,提高决策质量、效率和成本效益。 The modern pharmaceutical industry is transitioning from using traditional methods to advanced technologies like artificial intelligence,constantly incorporating modeling and simulation into drug discovery,development,design and optimization.In the context of drug clinical trials,clinical trial simulation(CTS)integrates relevant information and plays an important role in various stages of drug development.It has become a helpful tool to support decision-making and reduce failure occurrence of clinical trials,and has been widely recognized by pharmaceutical companies and regulatory authorities.By referring to the latest literature and guidelines from domestic and overseas,we reviewed the history,core methods and application range of CTS,aiming to help researchers better understand the application and value of this technology in drug research,especially new drug discovery.Hopefully,it can help improve the quality and efficiency of decision-making and increase cost-effectiveness.
作者 王思村 刘骏 陈亚飞 王忠 于亚南 WANG Si-cun;LIU Jun;CHEN Ya-fei;WANG Zhong;YU Ya-nan(Institute of Basic Research in Clinical Medicine,China Academy of Chinese Medical Sciences,Beijing 100700,China)
出处 《中国新药杂志》 CAS CSCD 北大核心 2024年第9期917-923,共7页 Chinese Journal of New Drugs
基金 中国中医科学院科技创新工程项目(CI2021A04707) 国家自然科学基金项目(82105052)。
关键词 临床试验模拟 模型引导的药物研发 建模和模拟 clinical trial simulation model-informed drug development modeling and simulation
  • 相关文献

参考文献7

二级参考文献69

  • 1黄晓晖,史军,李俊,谢海棠,郑青山,孙瑞元.药代动力学和药效动力学中数学建模与模拟的基本原理(1)[J].中国临床药理学与治疗学,2007,12(1):82-89. 被引量:9
  • 2黄晓晖,史军,李俊,宋国强,谢海棠,郑青山,孙瑞元.药代动力学和药效动力学中数学建模与模拟的基本原理(2)[J].中国临床药理学与治疗学,2007,12(3):334-341. 被引量:5
  • 3Skolnik JM, Barrett JS, Jayaraman B, et al. Shortening the timeline of pediatric phase I trials~ the roiling six design [J]. J Clin Oncol, 2008,26(2): 190--195. 被引量:1
  • 4Fetterly GJ, Grasela TH, Sherman JW, et al. Pharmacokinetic/pharmacodynamic modeling and simulation of neutropenia during phase I development of liposomc-entrapped paelitaxel [J]. Clin Cancer Res, 2008,14(18) :5856-5863. 被引量:1
  • 5Lockwood P, Ewy W, Hermann D, et al. Application of clinical trial simulation to compare proof-of- concept study designs for drugs with a slow onset of effect; an example in Alzheimefs disease[J]. Pharm Res, 2006 ,23(9) :2050-2059. 被引量:1
  • 6Pascal Girard. Clinical Trial Simulation: A Tool for Understanding Study Failures and Preventing Them [J].Basic Clin Pharmacol Toxicol, 2005, 96 (3): 228-234. 被引量:1
  • 7Dokoumetzidis A, Valsami G, Macheras P. Modelling and simulation in drug absorption proeesses[J].Xenobiodca, 2007,37 ( 10/11 ) : 1052- 1065. 被引量:1
  • 8Hale MD, Gillespie WR, Gupta, et al. Clinical trial simulation: streamlining your drug development process[J]. ApplClinTrials, 1996,5:35-40 . 被引量:1
  • 9Holford NH, Kimko HC, Monteleone JP, et al. Simulation of clinical trials[J]. Annu Rev Pharmacol Toxicol, 2000, 40 : 209 - 234. 被引量:1
  • 10Kimko H , Duffull S. Simulation for designing clin ieal trials: A Pharmacokinetic-pharmaeodynamic modeling perspective[M]. New York: Marcel Dekker ,2003. 被引量:1

共引文献59

同被引文献2

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部